| Code | Description | Claims | Beneficiaries | Total Paid |
|---|
| 99214 |
Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity |
237,663 |
188,904 |
$16.55M |
| 99213 |
Office or other outpatient visit for the evaluation and management of an established patient, low complexity |
21,621 |
17,616 |
$974K |
| 99204 |
Office or other outpatient visit for the evaluation and management of a new patient, moderate complexity |
3,479 |
2,967 |
$267K |
| 99205 |
Prolong outpt/office vis |
1,316 |
1,014 |
$194K |
| 64483 |
|
4,843 |
3,137 |
$151K |
| 99215 |
Prolong outpt/office vis |
1,017 |
799 |
$113K |
| 62323 |
|
1,784 |
1,230 |
$85K |
| 77002 |
|
3,451 |
2,192 |
$70K |
| 62321 |
|
1,110 |
703 |
$63K |
| 20610 |
|
4,215 |
2,647 |
$60K |
| 64636 |
|
1,517 |
1,049 |
$51K |
| 64494 |
|
1,968 |
1,375 |
$37K |
| 64484 |
|
1,476 |
993 |
$26K |
| 64495 |
|
1,021 |
650 |
$25K |
| 20611 |
|
579 |
341 |
$22K |
| 99245 |
|
81 |
78 |
$17K |
| 80307 |
Drug test(s), presumptive, any number of drug classes; immunoassay |
1,058 |
750 |
$12K |
| 99203 |
Office or other outpatient visit for the evaluation and management of a new patient, low complexity |
345 |
274 |
$11K |
| 64635 |
|
1,574 |
1,071 |
$11K |
| 64493 |
|
2,053 |
1,414 |
$11K |
| 01936 |
|
394 |
247 |
$11K |
| 27096 |
|
357 |
231 |
$8K |
| 99441 |
|
457 |
389 |
$6K |
| L0650 |
Lumbar-sacral orthosis, sagittal-coronal control, with rigid anterior and posterior frame/panel(s), posterior extends from sacrococcygeal junction to t-9 vertebra, lateral strength provided by rigid lateral frame/panel(s), produces intracavitary pressure to reduce load on intervertebral discs, includes straps, closures, may include padding, shoulder straps, pendulous abdomen design, prefabricated, off-the-shelf |
42 |
39 |
$5K |
| 76942 |
|
76 |
53 |
$4K |
| 99212 |
Office or other outpatient visit for the evaluation and management of an established patient, straightforward |
286 |
201 |
$3K |
| G0481 |
Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 8-14 drug class(es), including metabolite(s) if performed |
269 |
172 |
$3K |
| 99244 |
Office or other outpatient consultation, moderate to high complexity |
12 |
12 |
$2K |
| G0480 |
Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed |
29 |
28 |
$2K |
| 99442 |
|
140 |
115 |
$2K |
| J1030 |
Injection, methylprednisolone acetate, 40 mg |
363 |
255 |
$1K |
| 64491 |
|
29 |
24 |
$992.26 |
| 20553 |
|
30 |
24 |
$688.45 |
| 64490 |
|
59 |
40 |
$506.09 |
| 99211 |
Office or other outpatient visit for the evaluation and management of an established patient, minimal severity |
18 |
16 |
$407.04 |
| G0483 |
Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 22 or more drug class(es), including metabolite(s) if performed |
81 |
31 |
$100.18 |
| G2012 |
Brief communication technology-based service, e.g. virtual check-in, by a physician or other qualified health care professional who can report evaluation and management services, provided to an established patient, not originating from a related e/m service provided within the previous 7 days nor leading to an e/m service or procedure within the next 24 hours or soonest available appointment; 5-10 minutes of medical discussion |
25 |
25 |
$69.30 |
| 99497 |
|
12 |
12 |
$56.12 |
| 80305 |
|
223 |
197 |
$53.27 |
| J1020 |
Injection, methylprednisolone acetate, 20 mg |
14 |
12 |
$46.54 |
| G0482 |
Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 15-21 drug class(es), including metabolite(s) if performed |
122 |
76 |
$40.16 |
| J1100 |
Injection, dexamethasone sodium phosphate, 1 mg |
73 |
55 |
$11.63 |
| G8907 |
Patient documented not to have experienced any of the following events: a burn prior to discharge; a fall within the facility; wrong site/side/patient/procedure/implant event; or a hospital transfer or hospital admission upon discharge from the facility |
12 |
12 |
$0.00 |
| G8918 |
Patient without preoperative order for iv antibiotic surgical site infection (ssi) prophylaxis |
12 |
12 |
$0.00 |
| 64633 |
|
41 |
31 |
$0.00 |